The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Evaluating the role of autoSCT in patients with DLBCL who relapse after first-line therapy
Daniel Landsburg, MD, University of Pennsylvania, Philadelphia, PA, briefly discusses the important role of autologous stem cell transplantation (autoSCT) for patients with diffuse large B-cell lymphoma (DLBCL) who relapse after first-line treatment, particularly comparing this treatment to CAR-T therapy. Dr Landsburg also comments on the value of using advanced molecular testing to determine the best therapy for a patient. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
